ROBERT F. OZOLS, M.D., Ph.D.; BRIAN J. CORDEN, M.D., Ph.D.; JOAN JACOB, R.N., M.S.N.; MARGARET N. WESLEY, Ph.D.; YECHIAN OSTCHEGA, R.N., M.S.N.; ROBERT C. YOUNG, M.D.
To overcome the dose limiting toxicity of cisplatin we have administered high-dose cisplatin (200 mg/m2 body surface area in five divided daily doses with each dose administered in 250 mL of 3% saline) together with extensive hydration (250 mL/h normal saline with 20 meq KCI/L). In 17 previously untreated patients with poor prognosis nonseminomatous testicular cancer, 8 with tumor-associated obstructive uropathy, there was no statistically significant decrease in creatinine clearance or elevation of serum creatinine after three to four cycles of a high-dose cisplatin combination chemotherapy regimen. High-dose cisplatin in combination with vinblastine, bleomycin, and VP-16 produced an 88% complete response rate in these high-risk patients who are characterized primarily by the presence of advanced bulky lung and abdominal disease. Six patients with ovarian cancer who had a relapse after treatment with standard dose cisplatin regimens were treated with high-dose cisplatin and three partial responses were seen. Four patients had no adverse effects on renal function whereas 2 patients had transient elevations in serum creatinine (4 to 5 mg/dL). Hypertonic saline did not provide protection against the nonrenal toxicities of cisplatin.
OZOLS RF, CORDEN BJ, JACOB J, WESLEY MN, OSTCHEGA Y, YOUNG RC. High-Dose Cisplatin in Hypertonic Saline. Ann Intern Med. ;100:19–24. doi: 10.7326/0003-4819-100-1-19
Download citation file:
Published: Ann Intern Med. 1984;100(1):19-24.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use